New insights into the pathogenesis, diagnosis and treatment of human T-cell leukemia virus type 1-induced disease

Future Virology

Volumn 2, Issue 5, 2007, Pages 481-493

  Pandya, Devanshi ^a   Rahman, Saifur ^a   Wigdahl, Brian ^a   Khan, Zafar K ^a   Jain, Pooja ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Adult T cell leukemia; HTLV 1; HTLV 1 diagnosis; HTLV 1 LTR; HTLV 1 associated myelopathy tropical spastic paraparesis; miRNA pathway; Tax; Therapeutics; Transcription factors

Indexed keywords

ALPHA INTERFERON; ARSENIC TRIOXIDE; BACLOFEN; BORTEZOMIB; CARBOPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEPSIPEPTIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; INCADRONIC ACID; LAMIVUDINE; LBH 589; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PREDNISOLONE; RANIMUSTINE; TIZANIDINE; UNCLASSIFIED DRUG; VINCRISTINE; VINDESINE; VORINOSTAT; ZIDOVUDINE;

BLOOD; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; ENCEPHALITIS; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE RESPONSE; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; NEUROIMMUNOLOGY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; T CELL LEUKEMIA; VIROLOGY; VIRUS CELL INTERACTION; VIRUS INFECTION;

HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 34648834111     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.2.5.481     Document Type: Review

References (150)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl Acad. Sci. USA 77(12), 7415-7419 (1980).
2. Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC: Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell leukaemia. Nature 294(5838), 268-271 (1981).
3. Gallo RC: The discovery of the first human retrovirus: HTLV-1 and HTLV-2. Retrovirology 2(1), 17 (2005).
4. Ishida T, Yamamoto K, Omoto K, Iwanaga M, Osato T, Hinuma Y: Prevalence of a human retrovirus in native Japanese: evidence for a possible ancient origin. J. Infect. 11(2), 153-157 (1985).
5. Van Dooren S, Salemi M, Vandamme AM: Dating the origin of the African human T-cell lymphotropic virus type-1 (HTLV-1) subtypes. Mol. Biol. Evol. 18(4), 661-671 (2001).
6. Gessain A, Boeri E, Yanagihara R, Gallo RC, Franchini G: Complete nucleotide sequence of a highly divergent human T-cell leukemia (lymphotropic) virus type I (HTLV-I) variant from melanesia: genetic and phylogenetic relationship to HTLV-I strains from other geographical regions. J. Virol. 67(2), 1015-1023 (1993).
7. Yanagihara R, Saitou N, Nerurkar VR et al.: Molecular phylogeny and dissemination of human T-cell lymphotropic virus type I viewed within the context of primate evolution and human migration. Cell. Mol. Biol. (Noisy-le-grand) 41 (Suppl. 1). S145-S161 (1995).
8. Picard FJ, Coulthart MB, Oger J et al.: Human T-lymphotropic virus type 1 in coastal natives of British Columbia: phylogenetic affinities and possible origins. J. Virol. 69(11), 7248-7256 (1995).
9. Miura T, Yamashita M, Zaninovic V et al.: Molecular phylogeny of human T-cell leukemia virus type I and II of Amerindians in Colombia and Chile. J. Mol. Evol. 44(Suppl. 1), S76-S82 (1997).
10. Li HC, Fujiyoshi T, Lou H et al.: The presence of ancient human T-cell lymphotropic virus type I provirus DNA in an Andean mummy. Nat. Med. 5(12), 1428-1432 (1999).
11. Gurtsevich VE, Seniuta NB: HTLV-1 as a carcinogenic factor and instrument for studying the migratory history of ancient man. Vopr. Virusol. 43(2), 62-66 (1998).
12. Sonoda S, Li HC, Cartier L, Nunez L, Tajima K: Ancient HTLV type 1 provirus DNA of Andean mummy. AIDS Res. Hum. Retroviruses 16(16), 1753-1756 (2000).
13. Novak K: Ancient HTLV-1. Nat. Med. 5(12), 1357 (1999).
14. Gessain A, de The G: Geographic and molecular epidemiology of primate T lymphotropic retroviruses: HTLV-I. HTLV-II, STLV-I, STLV-PP, and PTLV-L. Adv. Virus Res. 47, 377-426 (1996).
15. Coulthart MB, Posada D, Crandall KA, Dekaban GA: On the phylogenetic placement of human T cell leukemia virus type 1 sequences associated with an Andean mummy. Infect. Genet. Evol. 6(2), 91-96 (2006).
16. Takatsuki K: Discovery of adult T-cell leukemia. Retrovirology 2(1), 16 (2005).
17. Barmak K, Harhaj E, Grant C, Alefantis T, Wigdahl B: Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration. Virology 308(1), 1-12 (2003).
18. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL: Global epidemiology of HTLV-I infection and associated diseases. Oncogene 24(39), 6058-6068 (2005).
19. Igakura T, Stinchcombe JC, Goon PK et al.: Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 299(5613), 1713-1716 (2003).
20. Barnard AL, Igakura T, Tanaka Y, Taylor GP, Bangham CR: Engagement of specific T-cell surface molecules regulates cytoskeletal polarization in HTLV-1-infected lymphocytes. Blood 106(3), 988-995 (2005).
21. Osame M, Janssen R, Kubota H et al.: Nationwide survey of HTLV-I-associated myelopathy in Japan: association with blood tranfusion. Ann. Neurol. 28(1), 50-56 (1990).
22. Kannagi M, Ohashi T, Hanabuchi S et al.: Immunological aspects of rat models of HTLV type 1 -infected T lymphoproliferative disease. AIDS Res. Hum. Retroviruses 16 (16), 1737-1740 (2000).
23. Lairmore MD, Silverman L, Ratner L: Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation. Oncogene 24(39), 6005-6015 (2005).
24. Matsuoka M, Jeang KT: Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat. Rev. Cancer 7(4), 270-280 (2007).
25. Asquith B, Bangham CR: Quantifying HTLV-I dynamics. Immunol. Cell Biol. (2007) (Epub ahead of print).
26. Gaudray G, Gachon F, Basbous J, Biard-Piechaczyk M, Devaux C. Mesnard JM: The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J. Virol. 76(24), 12813-12822 (2002).
27. Princler GL, Julias JG, Hughes SH, Derse D: Roles of viral and cellular proteins in the expression of alternatively spliced HTLV-1 pX mRNAs. Virology 317(1), 136-145 (2003).
28. Grassmann R, Aboud M, Jeang KT: Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 24(39), 5976-5985 (2005).
29. Bangham CR, Osame M: Cellular immune response to HTLV-1. Oncogene 24(39), 6035-9046 (2005).
30. Jacobson S: Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J. Infect. Dis. 186(Suppl. 2), S187-S192 (2002).
31. Doi K, Wu X, Taniguchi Y et al.: Preferential selection of human T-cell leukemia virus type I provirus integration sites in leukemic versus carrier states. Blood 106(3), 1048-1053 (2005).
32. Cavrois M, Leclercq I, Gout O, Gessain A, Wain-Hobson S, Wattel E: Persistent oligoclonal expansion of human T-cell leukemia virus type 1-infected circulating cells in patients with tropical spastic paraparesis/HTLV- 1 associated myelopathy. Oncogene 17(1), 77-82 (1998).
33. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K: Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc. Natl. Acad. Sci. USA 81(8), 2534-2537 (1984).
34. Takeda S, Maeda M, Morikawa S et al.: Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int. J. Cancer 109(4), 559-567 (2004).
35. Giam CZ, Xu YL: HTLV-1 tax gene product activates transcription via pre-existing cellular factors and cAMP responsive element. J. Biol. Chem. 264(26), 15236-15241 (1989).
36. Grant C, Nonnemacher M, Jain P et al.: CCAAT/enhancer-binding proteins modulate human T cell leukemia virus type 1 long terminal repeat activation. Virology 348(2), 354-369 (2006).
37. Giebler HA, Loring JE, van Orden K et al.: Anchoring of CREB binding protein to the human T-cell leukemia virus type 1 promoter: a molecular mechanism of Tax transactivation. Mol. Cell. Biol. 17(9), 5156-5164 (1997).
38. Wessner R, Yao J, Wigdahl B: Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer. Leukemia 11 (Suppl. 3), 10-13 (1997).
39. Hivin P, Gaudray G, Devaux C, Mesnard JM: Interaction between C/EBPβ and Tax down-regulates human T-cell leukemia virus type I transcription. Virology 318(2), 556-565 (2004).
40. Hirai H, Suzuki T, Fujisawa J, Inoue J, Yoshida M: Tax protein of human T-cell leukemia virus type I binds to the ankyrin motifs of inhibitory factor kappa B and induces nuclear translocation of transcription factor NF-kappa B proteins for transcriptional activation. Proc. Natl Acad. Sci. USA 91(9), 3584-3588 (1994).
41. Yao J, Wigdahl B: Human T cell lymphotropic virus type I genomic expression and impact on intracelluilar signaling pathways during neurodegenerative disease and leukemia. Front. Biosci. 5, D138-D168 (2000).
42. Yoshida M: Multiple viral strategies of HTLV- 1 for dysregulation of cell growth control. Annu. Rev. Immunol. 19, 475-496 (2001).
43. Johnson JM, Nicot C, Fullen J et al.: Free major histocompatiblitty, complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein. J. Virol. 75(13), 6086-6094 (2001).
44. Kim SJ, Nair AM, Fernandez S, Mathes L, Lairmore MD: Enhancement of LFA-1-mediated T cell adhesion by human T lymphotropic virus type 1 p12I1. J. Inmmunol. 176(9), 5463-5470 (2006).
45. Nicot C, Dundr M, Johnson JM et al.: HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication. Nat. Med. 10(2), 197-201 (2004).
46. Satou Y, Yasunaga J, Yoshida M, Matsuoka M: HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc. Natl. Acad. Sci. USA 103(3), 720-725 (2006).
47. Mahieux R, Suspene R, Delebecque F et al.: Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases. J. Gen. Virol. 86(Pt 9), 2489-2494 (2005).
48. Navarro F, Bollman B, Chen H et al.: Complementary function of the two catalytic domains of APOBEC3G.Virology 333(2), 374-386 (2005).
49. Sasada A, Takaori-Kondo A, Shirakawa K et al.: APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology 2, 32 (2005).
50. Harris RS, Bishop KN, Sheehy AM et al.: DNA deamination mediates innate immunity to retroviral infection. Cell 113(6), 803-809 (2003).
51. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424(6944), 99-103 (2003).
52. Mariani R, Chen D, Schrofelbauer B et al.: Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114(1), 21-31 (2003).
53. Harris RS, Liddament MT: Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4(11), 868-877 (2004).
54. Turelli P, Mangeat B, Jost S, Vianin S, Trono D: Inhibition of hepatitis B virus replication by APOBEC3G. Science 303(5665), 1829 (2004).
55. Russell RA, Wiegand HL, Moore MD, Schafer A, McClure MO, Cullen BR: Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family innate antiretroviral defense factors. J. Virol. 79(14), 8724-8731 (2005).
56. Doehle BP, Schafer A, Wiegand HL, Bogerd HP, Cullen BR: Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J. Virol. 79(13), 8201-8207 (2005).
57. Derse D, Hill SA, Princler G, Lloyd P, Heidecker G: Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc. Natl. Acad. Sci. USA 104(8), 2915-2920 (2007).
58. Khan RB, Bertorini TE, Levin MC: HTLV-1 and its neurological complications. Neurologist 7(5), 271-278 (2001).
59. Levin MC, Jacobson S: HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): a chronic progressive neurologic disease associated with immunologically mediated damage to the central nervous system. J. Neurovirol. 3(2), 126-140 (1997).
60. Barmak K, Harhaj EW, Wigdahl B: Mediators of central nervous system damage during the progression of human T-cell leukemia type I-associated myelopathy/tropical spastic paraparesis. J. Neurovirol. 9(5), 522-529 (2003).
61. Cartier L, Ramirez E: Presence of HTLV-I Tax protein in cerebrospinal fluid from HAM/TSP patients. Arch. Virol. 150(4), 743-753 (2005).
62. Alefantis T, Jain P, Ahuja J, Mostoller K. Wigdahl B: HTLV-1 Tax nucleocytoplasmic shuttling, Interaction with the secretory pathway, extracellular signaling, and implications for neurologic disease. J. Biomed. Sci. 12(6), 961-974 (2005).
63. Alefantis T, Barmak K, Harhaj EW, Grant C, Wigdahl B: Characterization of a nuclear export signal within the human T cell leukemia virus type I transactivator protein Tax. J. Biol. Chem. 278(24), 21814-21822 (2003).
64. Alefantis T, Mostoller K, Jain P, Harhaj E, Grant C, Wigdahl B: Secretion of the human T cell leukemia virus type I transactivator protein Tax. J. Biol. Chem. 280(17), 17353-17362 (2005).
65. Alefantis T, Flaig KE, Wigdahl B, Jain P: Interaction of HTLV- 1 Tax protein with calreticulin: implications for Tax nuclear export and secretion. Biomed. Pharmacother. 61(4), 194-200 (2007).
66. Ahuja J, Lepoutre V, Wigdahl B, Khan ZK, Jain P: Induction of pro-inflammatory cytokines by human T-cell leukemia virus type- 1 Tax protein as determined by multiplexed cytokine protein array analyses of human dendritic cells. Biomed. Pharmacother. 61, 1-8 (2007).
67. Cowan EP, Alexander RK, Daniel S, Kashanchi F, Brady JN: Induction of tumor necrosis factor α in human neuronal cells by extracellular human T-cell lymphotropic virus type 1 Tax. J. Virol. 71(9), 6982-6989 (1997).
68. Brady JN: Extracellular Tax1 protein stimulates NF-kB and expression of NF-kB-responsive Ig kappa and TNF β genes in lymphoid cells. AIDS Res. Hum. Retroviruses 8(5), 724-727 (1992).
69. Selmaj KW, Raine CS: Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23(4), 339-346 (1988).
70. Dhib-Jalbut S, Hoffman PM, Yamabe T et al.: Extracellular human T-cell lymphotropic virus type I Tax protein induces cytokine production in adult human microglial cells. Ann. Neurol. 36(5), 787-790 (1994).
71. Lee SM, Morcos Y, Jang H, Stuart JM. Levin MC: HTLV- 1 induced molecular mimicry in neurological disease. Curr. Top. Microbiol. Immunol. 296, 125-136 (2005).
72. Umehara F, Izumo S, Ronquillo AT, Matsumuro K, Sato E, Osame M: Cytokine expression in the spinal cord lesions in HTLV-I-associated myelopathy. J. Neuropathol. Exp. Neurol. 53(1), 72-77 (1994)
73. Kuroda Y, Matsui M: Cerebrospinal fluid interferon-γ is increased in HTLV-I-associated myelopathy. J. Neuroimmunol. 42(2), 223-226 (1993).
74. + cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 348(6298), 245-248 (1990).
75. Elovaara I, Koenig S, Brewah AY, Woods RM, Lehky T, Jacobson S: High human T cell lymphotropic virus type 1 (HTLV- 1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease. J. Exp. Med. 177(6), 1567-1573 (1993).
76. + lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detection. J. Immunol. 161(1), 482-488 (1998).
77. + cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J. Infect. Dis. 183(2), 197-205 (2001).
78. +) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood 99(1), 88-94 (2002).
79. Koenig S, Woods RM, Brewah YA et al.: Characterization of MHC class I restricted cytotoxic T cell responses to Tax in HTLV-1 infected patients with neurologic disease. J. Immunol. 151(7), 3874-3883 (1993).
80. Parker CE, Nightingale S, Taylor GP, Weber J, Bangham CR: Circulating anti-Tax cytotoxic T lymphocytes from human T-cell leukemia virus type I-infected people, with and without tropical spastic paraparesis, recognize multiple epitopes simultaneously. J. Virol. 68(5), 2860-2868 (1994).
81. +) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc. Natl Acad. Sci. USA 95(13), 7568-7573 (1998).
82. + T cells in cerebrospinal fluid from patients with HAM/ TSP. Ann. Neurol. 50(6). 807-812 (2001).
83. Richardson JH, Hollsberg P, Windhagen A, Child LA, Hafler DA, Lever AM: Variable immortalizing potential and frequent virus latency in blood-derived T-cell clones infected with human T-cell leukemia virus type I. Blood 89(9), 3303-3314 (1997).
84. + lymphocytes distinguishes between individuals with a high or low proviral load of human T cell lymphotropic virus type 1. J. Immunol. 173(8), 5121-5129 (2004).
85. + lymphocytes correlate with the proviral load in peripheral blood of infected individuals. J. Neuroimmunol. 102(2), 208-215 (2000).
86. Jeffery KJ, Usuku K, Hail SE et al.: HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc. Natl Acad. Sci. USA 96(7), 3848-3853 (1999).
87. Jeffery KJ, Siddiqui AA, Bunce M et al.: The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J. Immunol. 165(12), 7278-7284 (2000).
88. Mostoller K, Norbury CC, Jain P, Wigdahl B: Human T-cell leukemia virus type I Tax induces the expression of dendritic cell markers associated with maturation and activation. J. Neurovirol. 10(6), 358-371 (2004).
89. Jain P, Ahuja J, Khan ZK et al.: Activation and maturation of human monocyte-derived dendritic cells by extracelluar Tax protein of human T cell leukemia virus type 1. J. Leukoc. Biol. 82, 1-20 (2007).
90. Ahuja J, Kampani K, Datta S, Wigdahl B, Flaig KE, Jain P: Use of human antigen presenting cell gene array profiling to examine the effect of human T-cell leukemia virus type 1 Tax on primary human dendritic cells. J. Neurovirol. 12(1), 47-59 (2006).
91. Makino M, Shimokubo S, Wakamatsu SI, Izumo S, Baba M: The role of human T-lymphotropic virus type 1 (HTLV- 1)- infected dendritic cells in the development of HTLV-1-associated myelopathy/tropical spastic paraparesis. J. Virol. 73(6), 4575-4581 (1999).
92. Feuer G, Fraser JK, Zack JA, Lee F, Feuer R, Chen IS: Human T-cell leukemia virus infection of human hematopoietic progenitor cells: maintenance of virus infection during differentiation in vitro and in vivo. J. Virol. 70(6), 4038-4044 (1996).
93. Mikovits J, Ruscetti F, Zhu W, Bagni R, Dorjsuren D, Shoemaker R: Potential cellular signatures of viral infections in human hematopoietic cells. Dis. Markers 17(3), 173-178 (2001).
94. Hoffman PM, Dhib-Jalbut S. Mikovits JA et al.: Human T-cell leukemia virus type I infection of monocytes and microglial cells in primary human cultures. Proc. Natl Acad. Sci. USA 89(24), 11784-11788 (1992).
95. Szymocha R. Brisson C, Bernard A, Akaoka H, Belin MF, Giraudon P: Long-term effects of HTLV-1 on brain astrocytes: sustained expression of Tax-1 associated with synthesis of inflammatory mediators. J. Neurovirol. 6(4), 350-357 (2000).
96. Hirayama M, Miyadai T, Yokochi T et al.: Infection of human T-lymphotropic virus type I to astrocytes in vitro with induction of the class II major histocompatibility complex. Neurosci. Lett. 92(1), 34-39 (1988).
97. Yamada M, Watabe K, Saida T, Kim SU: Increased susceptibility of human fetal astrocytes to human T-lymphotropic virus type I in culture. J. Neuropathol. Exp. Neurol. 50(2), 97-107 (1991).
98. + HTLV-1-specific cytotoxic T cells. J. Virol. 71(12). 9143-9149 (1997).
99. Koyanagi Y, Itoyama Y, Nakamura N et al.: In vivo infection of human T-cell leukemia virus type I in non-T cells. Virology 196(1), 25-33 (1993).
100. Grant C, Jain P, Nonnemacher M et al.: AP-1-directed human T cell leukemia virus type 1 viral gene expression during monocytic differentiation. J. Leukoc. Biol. 80(3), 640-650 (2006).
101. Grant C, Barmak K, Alefantis T, Yao J, Jacobson S, Wigdahl B: Human T cell leukemia virus type I and neurologic disease: events in bone marrow, peripheral blood, and central nervous system during normal immune surveillance and neuroinflammation. J. Cell. Physiol. 190(2), 133-159 (2002).
102. Lillehoj EP, Alexander SS, Dubrule CJ et al.: Development and evaluation of a human T-cell leukemia virus type I serologic confirmatory assay incorporating a recombinant envelope polypeptide. J. Clin. Microbiol. 28(12), 2653-2658 (1990).
103. Varma M, Rudolph DL, Knuchel M et al.: Enhanced specificity of truncated transmembrane protein for serologic confirmation of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infections by Western blot (immunoblot) assay containing recombinant envelope glycoproteins. J. Clin. Microbiol. 33(12), 3239-3244 (1995).
104. Vrielink H, Zaaijer HL, Van der Poel CL et al.: New strip immunoblot for the confirmation of HTLV-I/II infection. Vox Sang. 70(2), 114-116 (1996).
105. Zrein M, Louwagie J, Boeykens H et al.: Assessment of a new immunoassay for serological confirmation and discrimination of human T-cell lymphotropic virus infections. Clin. Diagn. Lab. Immunol. 5(1), 45-49 (1998).
106. Ikeda M, Fujino R, Matsui T, Yoshida T, Komoda H, Imai J: A new agglutination test for serum antibodies to adult T-cell leukemia virus. Gann 75(10), 845-848 (1984).
107. Thorstensson R, Albert J, Andersson S: Strategies for diagnosis of HTLV-I and -II. Transfusion 42(6), 780-791 (2002).
108. Taguchi H, Sawada, T, Fujishita M, Morimoto T, Niiya K, Miyoshi I: Enzyme-linked immunosorbent assay of antibodies to adult T-cell leukemia-associated antigens. Gann 74(2), 185-187 (1983).
109. Yamaguchi K, Yonemura Y, Okabe H et al.: Detection of anti-human T-lymphotropic virus type I antibody in whole blood by a novel counting immunoassay. Clin. Chem. 49(2), 275-280 (2003).
110. Dehee A, Cesaire R, Desire N et al.: Quantitation of HTLV-I proviral load by a TaqMan real-time PCR assay. J. Virol. Methods 102(1-2), 37-51 (2002).
111. Lee TH, Chafets DM, Busch MP, Murphy EL: Quantitation of HTLV-I and II proviral load using real-time quantitative PCR with SYBR Green chemistry. J. Clin. Virol. 31(4), 275-282 (2004).
112. Matsuzaki T, Nakagawa M, Nagai M et al.: HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. J. Neurovirol. 7(3), 228-234 (2001).
113. Kamihira S, Dateki N, Sugahara K et al.: Significance of HTLV-1 proviral load quantification by real-time PCR as a surrogate marker for HTLV-1-infected cell count. Clin. Lab. Haematol. 25(2), 111-117 (2003).
114. Olindo, S, Lezin A, Cabre P et al.: HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: a marker of disease progression. J. Neurol. Sci. 237(1-2), 53-59 (2005).
115. Sales MM, Bezerra CN, Hiraki Y, Melo NB, Reboucas NA: Clonally rearranged T-cell receptor β chain genes in HTLV-I carriers with abnormal, non-flower-like, lymphocytes. Eur. J. Haematol. 75(4), 280-287 (2005).
116. Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-1987). Br. J. Haematol. 79(3), 428-437 (1991).
117. Nicot C: Current views in HTLV-I-associated adult T-cell leukemia/ lymphoma. Am. J. Hematol. 78(3), 232-239 (2005).
118. Shuh M, Beilke M: The human T-cell leukemia virus type 1 (HTLV-1): new insights into the clinical aspects and molecular pathogenesis of adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/ HTLV-associated myelopathy (TSP/HAM). Microsc. Res. Tech. 68(3-4), 176-196 (2005).
119. Ohshima K: Pathological features of diseases associated with human T-cell leukemia virus type I. Cancer Sci. 98(6), 772-778 (2007).
120. Isomoto H, Ohnita K, Mizuta Y et al.: Clinical and endoscopic features of adult T-cell leukemia/lymphoma with duodenal involvement. J. Clin. Gastroenterol. 33(3), 241-246 (2001).
121. Hishizawa M, Imada K, Sakai T, Ueda M, Hori T, Uchiyama T: Serological identification of adult T-cell leukaemia-associated antigens. Br. J. Haematol. 130(3), 382-390 (2005).
122. Osame M, Usuku K, Izumo S et al.: HTLV-I associated myelopathy, a new clinical entity. Lancet 1(8488), 1031-1032 (1986).
123. Puccioni-Sohler M, Yamano Y, Rios M et al.: Differentiation of HAM/TSP from patients with multiple sclerosis infected with HTLV-I. Neurology 68(3). 206-213 (2007).
124. De Castro-Costa CM, Araujo AQ, Barreto MM et al.: Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res. Hum. Retroviruses 22(10), 931-935 (2006).
125. Gessain A, Caudie C, Gout O et al.: Intrathecal synthesis of antibodies to human T lymphotropic virus type I and the presence of IgG oligoclonal bands in the cerebrospinal fluid of patients with endemic tropical spastic paraparesis. J. Infect. Dis. 157(6), 1226-1234 (1988).
126. Ramirez E, Cartier L, Torres M, Barria M: Temporal dynamics of human T-lymphotropic virus type I tax mRNA and proviral DNA load in peripheral blood mononuclear cells of human T-lymphotropic virus type I-associated myelopathy patients. J. Med. Virol. 79(6), 782-790 (2007).
127. Best I, Adaui V, Verdonck K et al.: Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru. Clin. Exp. Immunol. 146(2), 226-233 (2006).
128. Taylor GF, Matsuoka M: Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 24(39), 6047-6057 (2005).
129. Kchour G, Makhoul NJ. Mahmoudi M et al.: Zidovudine and interferon-α treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk. Lymphoma 48(2), 330-336 (2007).
130. Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M: Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 18(8), 1357-1363 (2004).
131. Mitra-Kaushik S, Harding JC, Hess JL, Ratner L: Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood 104(3), 802-809 (2004).
132. Mori N, Matsuda T, Tadano M et al.: Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. J. Virol. 78(9), 4582-4590 (2004).
133. Nishioka C, Ikezoe T, Yang J et al.: Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappa B. Leuk. Res. (2007) (Epub ahead of print).
134. Ishikawa C, Matsuda T, Okudaira T et al.: Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway. Br. J. Haematol. 136(3), 424-432 (2007).
135. Nishioka C, Ikezoe T, Yang J. Koeffler HP, Taguchi H: Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T cells via inhibition of the nuclear factor-kappa B signal pathway. Leukemia 21(5), 1044-1049 (2007).
136. Dbaibo GS, Kfoury Y, Darwiche N et al.: Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity. Haematologica 92(6), 753-762 (2007).
137. Hasegawa H, Yamada Y, Komiyama K et al.: Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells. Blood 107(2), 679-688 (2006).
138. Waldmann TA, White JD, Goldman CK et al.: The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 82(6), 1701-1712 (1993).
139. Zhang Z, Zhang M. Ravetch JV, Goldman C, Waldmann TA: Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood 102(1), 284-288 (2003).
140. + helper T lymphocytes. Clin. Cancer Res. 12(12), 3814-3822 (2006).
141. Karni M. Hamaki T, Miyakoshi S et al.: Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/ lymphoma. Br. J. Haematol. 120(2), 304-309 (2003).
142. Okamura J, Utsunomiya A, Tanosaki R et al.: Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 105(10), 4143-4145 (2005).
143. Taylor GP, Hall SE, Navarrete S et al.: Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J. Virol. 73(12), 10289-10295 (1999).
144. Machuca A, Rodes B, Soriano V: The effect of antiretroviral therapy on HTLV infection. Virus Res. 78(1-2), 93-100 (2001).
145. Oh U, Yamano Y, Mora CA et al.: Interferon-β1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann. Neurol. 57(4). 526-534 (2005).
146. Fukushima N, Nishiura Y, Nakamura T, Kohno S, Eguchi K: Blockade of IL-2 receptor suppresses HTLV-I and IFN-γ expression in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Intern. Med. 46(7), 347-351 (2007).
147. Feng J, Misu T, Fujihara K et al.: Interferon-α significantly reduces cerebrospinal fluid CD4 cell subsets in HAM/TSP. J. Neuroimmunol. 141(1-2), 170-173 (2003).
148. Saito M, Nakagawa M, Kaseda S et al.: Decreased human T lymphotropic virus type I (HTLV-1) provirus load and alteration in T cell phenotype after interferon-α therapy for HTLV-1-associated myelopathy/tropical spastic paraparesis. J. Infect. Dis. 189(1), 29-40 (2004).
149. + T lymphocytes in patients with HTLV-I-associated myelopathy. J. Neuroimmunol. 127(1-2), 134-138 (2002).
150. Tozser J, Weber IT: The protease of human T-cell leukemia virus type-1 is a potential therapeutic target. Curr. Pharm. Des. 13(12), 1285-1294 (2007).